Antibody-cytotoxic agent conjugates for cancer therapy (Q36316831)

13 August 2017

1 reference

title

Antibody-cytotoxic agent conjugates for cancer therapy (English)

1 reference

13 August 2017

0 references

Jin Chen

1

1 reference

13 August 2017

Stanislav Jaracz

2

1 reference

13 August 2017

Xianrui Zhao

3

1 reference

13 August 2017

Shuyi Chen

4

1 reference

13 August 2017

Iwao Ojima

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Expert Opinion on Drug Delivery

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

5

1 reference

13 August 2017

873-890

1 reference

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Recombinant immunotoxins for the treatment of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Recent advances with monoclonal antibody drug targeting for the treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Delivery of molecular and cellular medicine to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Enabling ScFvs as multi-drug carriers: a dendritic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

VIP-ellipticine derivatives inhibit the growth of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Production of a monoclonal antibody-mitomycin C conjugate, utilizing dextran T-40, and its biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Microtubule dynamics: taking aim at a moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Tumor specific novel taxoid-monoclonal antibody conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

The urokinase receptor as a potential target in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

The history of ricin, abrin and related toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Identification of amino acid residues of abrin-a A chain is essential for catalysis and reassociation with abrin-a B chain by site-directed mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Isolation and properties of abrin: a toxic protein inhibiting protein synthesis. Evidence for different biological functions of its two constituent-peptide chains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

New hydrazone derivatives of adriamycin and their immunoconjugates--a correlation between acid stability and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Small molecule toxins targeting tumor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Glutathione deficiency produced by inhibition of its synthesis, and its reversal; Applications in research and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Perspectives on anti-HER monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Synthesis and structure-activity relationships of new second-generation taxoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Synthesis and Structure−Activity Relationships of Nonaromatic Taxoids: Effects of Alkyl and Alkenyl Ester Groups on Cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Efficient Asymmetric Syntheses of β-Lactams Bearing a Cyclopropane or an Epoxide Moiety and Their Application to the Syntheses of Novel Isoserines and Taxoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.5.873

21 January 2018

Identifiers

DOI

10.1517/17425247.2.5.873

1 reference

13 August 2017

1 reference